3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
15
Prostatic Neoplasms, Castration-Resistant
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Uveal Melanoma
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Penile Neoplasms
1
Ovarian Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
26
Magnetic Resonance Spectroscopy
14
Nivolumab
13
Docetaxel
13
Specimen Handling
11
Radiotherapy
9
Paclitaxel
9
Radiosurgery
8
Early Intervention, Educational
8
Cyclophosphamide
8
Gemcitabine
7
atezolizumab
6
Taxes
6
Surveys and Questionnaires
6
Standard of Care
6
Psychiatric Rehabilitation
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Pemetrexed
5
Methods
5
motexafin gadolinium
4
fludarabine
4
X-Rays
4
Interviews as Topic
4
Immunoglobulin G
4
Fluorouracil
4
Educational Status
4
Cisplatin
4
Biopsy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
niraparib
×
Genitourinary
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts